Fujifilm Invests in Biopharmaceutical Production Capacity

News
Article

Fujifilm increases capacity of its Bio-CDMO business with an expansion of production in North Carolina.

Fujifilm plans to invest approximately JPY 10 billion (approximately US$90 million) to expand its biopharmaceutical contract development and manufacturing organization (CDMO) business, FUJIFILM Diosynth Biotechnologies (FDB), the company announced on Jan. 7, 2019. 

This investment will include the expansion of existing production facilities at its North Carolina location. Further investments are planned at the company’s other locations.

Investments will include the addition of 2000-L single-use cell-culture manufacturing trains, cell-culture purification suites, and new microbial recovery suites to its existing facilities in North Carolina. These additions will increase cell-culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% at its North Carolina location. The company expects that the increased production capacity will be ready for cGMP manufacture by early 2020. Fujifilm has committed to grow its CDMO business to meet a JPY 100 billion sales target by March 2024. 

Source: Fujifilm

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Related Content